

# PROVIDER BULLETIN

## PROVIDER INFORMATION



October 1, 2024

### Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans Managed by Blue Cross and Blue Shield of Alabama

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. Make sure your voice is heard by providing feedback directly to us.

#### How to Submit Comments on Draft Medical Policies

[Complete our medical policy feedback form](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) online at <https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback> or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center  
Attn: Health Management - Medical Policy  
P.O. Box 10527  
Birmingham, AL 35202  
Fax: 205-220-0878

#### Draft Medical Policies

Draft medical policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
MP-053	Bariatric Surgery
MP-058	Panniculectomy/Excision of Redundant Skin or Tissue
MP-060	Hyperbaric Oxygen Therapy
MP-118	Dermabrasion
MP-123	Compression Devices in the Outpatient or Home Setting
MP-191	Bone Mineral Density Testing
MP-685	Gender Affirming Procedures
MP-763	High Intensity Laser Therapy for Chronic Musculoskeletal Pain Conditions and Bell's Palsy

#### Draft Provider-Administered Drug Policies

Draft provider-administered drug policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) and [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

<b>Policy #</b>	<b>Policy Title</b>
PH-90763	Kisunla™ (donanemab-azbt)
PH-90762	Piasky™ (crovalimab-akkz)
PH-90026	Aflibercept: Eylea®; Eylea® HD; Opuviz™; Yesafili™; Ahzantive™
PH-90018	Beriner® (C1 Esterase Inhibitor, Human)
PH-90168	Cinryze® (C1 Esterase Inhibitor, Human)
PH-90229	Cosentyx® (secukinumab)
PH-90114	Eculizumab: Soliris®; Bkemy™
PH-90061	Hyaluronic Acid Derivatives: Durolane®, Euflexxa™, Gel-One®, GelSyn-3™, GenVisc 850®, Hyalgan™, Hymovis®, Monovisc®, Orthovisc™, Synjoynt, Supartz/Supartz FX™, Synvisc™, Synvisc-One™, Triluron™, TriVisc™, VISCO-3™
PH-90177	Ilaris® (canakinumab)
PH-90358	Ilumya™ (tildrakizumab-asmn)
PH-90167	Kalbitor® (ecallantide)
PH-90091	Orencia® (abatacept)
PH-90109	Rituximab: Rituxan®, Truxima®, Ruxience®, Riabni™
PH-90207	Ruconest® (C1 Esterase Inhibitor [recombinant])
PH-90059	SCIG (immune globulin SQ): Hizentra®, Gammagard Liquid®, Gamunex®-C, Gammaked™, HyQvia®, Cuvitru®, Cutaquig®, Xembify®
PH-90671	Skyrizi® (risankizumab-rzaa)
PH-90291	Spinraza™ (nusinersen)
PH-90481	Spravato (esketamine)
PH-90002	Tocilizumab: Actemra®; Tofidence™; Tyenne®
PH-90117	Ustekinumab: Stelara®; Wezlana™; Selarsdi™; Pyzchiva®
PH-90468	Zolgensma (onasemnogene abeparvovec-xioi)